Generate Biomedicines

Historical price data

Generate Biomedicines is a Flagship Pioneering company on a mission to program biology, using its proprietary Generate Platform to create novel protein therapeutics with unprecedented speed and precision. The company achieved a significant validation milestone with its IPO in March 2026, raising capital to advance a diversified pipeline led by GB-0895, a long-acting anti-TSLP antibody now in global Phase 3 studies for severe asthma. Its strategy leverages a continuous learning loop that integrates computational design with high-throughput experimental validation, aiming to build a broad portfolio of internally developed and partnered programs across immunology, oncology, and beyond.

The Generate Platform™ is a closed-loop, generative AI system that designs novel protein therapeutics from first principles through a continuous cycle of computational generation, physical construction, experimental measurement, and machine learning refinement.